Blood Dopamine Levels Research Articles

Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial

HIV-associated neurocognitive disorders (HAND) persist in the era of antiretroviral therapy (ART). Thus, ART does not completely halt or reverse the pathological processes behind HAND. Adjuvant mitigating treatments are, therefore, prudent. Lithium treatment is known to promote neuronal brain–derived neurotrophic factors (BDNF). Lithium is also an inhibitor of glycogen synthase kinase-3 beta (GSK-3-β). We analyzed biomarkers obtained from participants in a randomized placebo-controlled trial of lithium in ART-treated individuals with moderate or severe HAND. We assayed markers at baseline and 24 weeks across several pathways hypothesized to be affected by HIV, inflammation, or degeneration. Investigated biomarkers included dopamine, BDNF, neurofilament light chain, and CD8 + lymphocyte activation (CD38 + HLADR +). Alzheimer’s Disease (AD) biomarkers included soluble amyloid precursor protein alpha and beta (sAPPα/β), Aβ38, 40, 42, and ten other biomarkers validated as predictors of mild cognitive impairment and progression in previous studies. These include apolipoprotein C3, pre-albumin, α1-acid glycoprotein, α1-antitrypsin, PEDF, CC4, ICAM-1, RANTES, clusterin, and cystatin c. We recruited 61 participants (placebo = 31; lithium = 30). The age baseline mean was 40 (± 8.35) years and the median CD4 + T-cell count was 498 (IQR: 389–651) cells/μL. Biomarker concentrations between groups did not differ at baseline. However, both groups’ blood dopamine levels decreased significantly after 24 weeks (adj. p < 002). No other marker was significantly different between groups, and we concluded that lithium did not confer neuroprotection following 24 weeks of treatment. However, the study was limited in duration and sample size.

Clinical effectiveness of fecal microbiota transplantation combined with nutritional support and psychological intervention in patients with "Tetralogy of Tongji"

Objective: To summarize and analyze the clinical effect of fecal microbiota transplantation (FMT) combined with nutritional support and psychotherapy in patients with "Tetralogy of Tongji" (comprising chronic gastrointestinal dysfunction, mental and psychological disorders, malnutrition, and endocrine disorders). Methods: A longitudinal study was conducted. The inclusion criteria were as follows: (1) patients were under 70 years of age; (2) patients exhibited chronic gastrointestinal dysfunction (in accordance with the Rome IV diagnostic criteria for irritable bowel syndrome ie. chronic functional constipation, diarrhea, abdominal pain and abdominal distention) with onset occurring more than one year previously; (3) patients exhibited malnutrition (body mass index ≤ 18.5 kg/m2); (4) patients exhibited depression, anxiety, or state as diagnosed by a psychologist using the Hamilton anxiety rating scale (HAMA) and the Hamilton depression scale (HAMD); (5) patients were women of childbearing age with amenorrhea or menstrual disorder with a duration ≥6 months. Patients were excluded if they exhibited gastrointestinal bleeding, short bowel syndrome, radiation-induced intestinal injury, intestinal obstruction or inflammatory bowel disease, recurrent/metastatic tumors, systemic infectious diseases, life-threatening systemic comorbidities, intorlerate to nasojejunal, percutaneous gastrostomy / jejunostomy or FMT. The clinical data of 43 patients at Shanghai Tenth People's Hospital exhibiting the "Tetralogy of Tongji" and who received microflora transplantation combined with nutritional support and psychotherapy from June 2017 to June 2021 was prospectively collected. There were 12 males and 31 females with a mean age of 35.2±16.7 years. All 43 patients had chronic gastrointestinal dysfunction. Of these, 24 patients had depression and 19 had anxiety. There were 26 women of reproductive age, including 13 cases of menstrual disorder and 9 cases of amenorrhea. The treatment intervention was a combination of FMT (microflora solution or microflora capsule), nutritional support (enteral nutrition) and psychological intervention. The following were assessed before treatment and 1, 3, 6 months after treatment: (1) gastrointestinal function was assessed using the gastrointestinal symptoms rating scale (GSRS), where a higher score is indicative of more serious gastrointestinal symptoms, and the gastrointestinal quality of life index (GIQLI), where a higher score is indicative of higher quality of life; (2) psychological status was assessed using HAMA and HAMD scores, where a lower score is indicative of reduced severity of anxiety or depression symptoms, respectively; (3) nutritional status was assessed by measurements of total blood protein, albumin, fibrinogen and prealbumin, as well as measurements of body mass and body mass index (BMI); (4) neuroendocrine function was assessed by measurement of blood levels of cortisol, dopamine and noradrenaline, as well as menstruation in women of reproductive age. Results: The follow-up rates at 1, 3 and 6 months after treatment were 90.7% (39/43), 72.1% (31/43) and 55.8% (24/43), respectively. The total effective rate for chronic gastrointestinal dysfunction was 81.4% (35/43), of which the average GSRS score decreased from 29.35±3.56 before treatment to 18.25±2.56 in the sixth month (P<0.001). The average GIQLI score increased from 56.23±10.34 before treatment to 91.04±20.39 in the sixth month (P<0.001). All patients had malnutrition before treatment. After 6 months, their body weight had increased from 40.61±8.88 kg to 50.45±6.23 kg (P<0.001), and BMI had increased from 15.17±1.87 kg/m2 to 19.58±1.42 kg/m2 (P<0.001). The average total protein level was 60.99± 5.99 g/L before treatment. After 6 months, this had increased to 64.21±4.23 g/L (F=2.715, P=0.022). The average prealbumin level increased from 150.14±56.04 mg/L before treatment to 258.17±86.94 mg/L after 6 months (F=15.124, P<0.001). In this study, 24 patients with depression/depressed state were included. After treatment, the average HAMD score in these patients decreased from 22.79±6.63 before treatment to 9.92±7.24 after 6 months (P<0.001). There were 19 patients with anxiety disorder/anxiety state. After treatment, the average HAMA score in these patients decreased from 17.15±4.34 before treatment to 7.73±4.10 after 6 months (P<0.001). Observing the endocrine efficacy of 26 women of childbearing age, it was found that the effective rate of this treatment on endocrine regulation was 69.2% (18/26). Although there was no significant change in blood cortisol levels after 6 months, average blood dopamine levels decreased from 32.91±10.65 nmol/L before treatment to 13.02±5.58 nmol/L after 6 months (P<0.001). Average blood norepinephrine levels decreased from 49.75±15.23 ng/L before treatment to 19.21±9.58 ng/L after 6 months (P<0.001). Conclusion: The strategy of FMT combined with nutritional support and psychological intervention is effective in improving the symptoms of the "Tetralogy of Tongji".

Differential diagnosis of sleep disorders in the presence of chronic mercury intoxication

Abstract. Insomnia is a widespread pathological condition in the general population, which has numerous social and medical consequences. Sleep disorders in patients with chronic mercury intoxications are much more common than in the general population. This study aimed to determine the most significant differential diagnostic criteria for sleep disorders in patients with chronic mercury intoxications for their further effective treatment. In this regard, we examined 30 patients with chronic mercury intoxications, whose age averaged 56 0.71 years, and 30 patients of the control group, whose age averaged 54 0.66. All patients underwent clinical, neurological, polysomnographic, and psychological examinations, and neurotransmitters were determined in the blood. Discriminant analysis based on polysomnography, psychological testing and neurotransmitter metabolism revealed significant differences in the examined groups of patients for the following indicators: total sleep time (decreased in the chronic mercury intoxication group) and wake within sleep (increased in the chronic mercury intoxication group) based on polysomnography, blood dopamine level (increased in the chronic mercury intoxication group) as well as reactive anxiety level according to the Spielberger-Khanin scale (increased in the chronic mercury intoxication group). Taking into account the data obtained, it is possible to improve approaches to the diagnosis and treatment of insomnia in the presence of chronic mercury intoxication.

Impact of Obesity on Physical Activity

BACKGROUND: Obesity occurs due to an imbalance between the calories and the energy released. On the animal model, obesity is considered as the ground for low physical activity. This is caused by low dopamine D2 receptor in the striatum. However, this suggestion is still unproven in the human condition. AIM: The aim of this study was to find out difference in dopamine expression in obese subjects compared to non-obese subjects when triggered by the stimuli of physical activity. METHODS: This is a quasi-experimental study. The sample was obese and non-obese (control) female who met inclusion and exclusion criteria. Before treatment was given, subjects were asked to fill out a depression, anxiety, and exercise motivation questionnaire. All subjects were tested for vital signs, anthropometrics, and neurological examinations to determine the initial condition. Then, the subjects saw video about physical activity and were taken for blood to measure blood dopamine levels using enzyme-linked immunosorbent assay. Differences in dopamine levels between the obese and control groups were analyzed using independent t-test. The relationship between dopamine levels and exercise motivation was analyzed using Pearson. RESULTS: The obese group’s dopamine level was 71.19 ±3.02ng/ml and the control group was 81.15 ± 3.17ng/ml (independent t-test, p = 0.032). The obese group’s motivation score was 58.46 ± 1.59 and the control group score was 62.38 ± 1.54 (independent t-test, p = 0.09). Furthermore, there was no correlation between dopamine levels and motivation scores (Pearson test, p = 0.09). CONCLUSION: There are significant differences in dopamine levels between the obese group and the control group but no correlation between dopamine levels and exercise motivation scores.

Mild anxiety and depression related to elevated dopamine level

BackgroundDopamine is an important neurotransmitter that plays a role in the pathogenesis of anxiety and depression. Dopamine secretion occurs when there is a pleasurable stimulus. Blood dopamine levels have the potential to be developed as biomarkers of depression or anxiety, but previous studies related to the relationship between dopamine levels and levels of anxiety and depression are still controversial. The purpose of this study was to determine the correlation between anxiety and depression score with dopamine level in young adults. MethodsThis was an observational cross sectional study. A total of 43 subjects aged 18 to 40 years were recruited by consecutive non-random sampling according to inclusion and exclusion criteria. Anxiety and depression were assessed using the Beck anxiety inventory and Beck depression inventory-II questionnaire. Dopamine plasma level was measured using the enzyme-linked immunosorbent assay (ELISA). The Spearman rho correlation test was used to analyze the data and p&lt;0.05 was considered significant.Results The median dopamine levels in respondents with mild, moderate and severe anxiety were respectively: 77.79; 63.43; 62.51 ng/mL (p=0.043). The median dopamine levels in respondents with reasonable depression, mood disorder, moderate and severe depression were respectively: 79.2; 61,32; 62,51; 60.24 (p=0.001). Correlation test results showed a weak correlation between dopamine and anxiety (r=- 0.310) and a moderate correlation for depression (r=-0.505).ConclusionMild anxiety and depression were associated with elevated dopamine level in young adults. Further studies are required to confirm the role of dopamine metabolism in anxiety and depression in young adults.

Blood dopamine level enhanced by caffeine in men after treadmill running.

The aim of this study was to investigate the plasma dopamine and serum serotonin levels in humans with and without caffeine (CAFF) ingestion during treadmill running exercise. Thirty male volunteers participated in the randomized experiment involving two groups: CON (n = 15, 200 mL of tap water) versus CAFF (n = 15, 3 mg/kg CAFF and 200 mL tap water). After treadmill running, the dopamine level was significantly increased in the CAFF group (P < 0.01) and was significantly higher than in the CON group (P < 0.01). Serotonin was significantly increased in both groups after treadmill running (P < 0.05). However, serotonin levels showed no significant statistical difference between the groups. Prolactin and cortisol were significantly increased in both groups after treadmill running (P < 0.01). However, there was no significant statistical difference between groups. β-endorphin level was significantly increased in the CAFF group at after treadmill running (P < 0.01) and was significantly higher than in CON after treadmill running (P < 0.01). In conclusion, 3 mg/kg CAFF ingestion before treadmill running stimulated dopamine release without inhibiting serotonin, which may reduce central fatigue.

Relationship between blood dopamine level, behavioral and emotional status of puberty-age children with obesity and normal body mass

Relationship between blood dopamine level, behavioral and emotional status of puberty-age children with obesity and normal body mass

Catecholamine levels in a Ramadan fasting model in rats: a case control study

ABSTRACTEating habits as well as physical exercise are very important for a healthy lifespan. Ramadan-type fasting, which is food and water avoidance during the daylight period for four weeks, has drawn attention due to its positive impacts on metabolism and health. The aim of this study was to compare the blood and urine catecholamine (CA) levels in fasting and non-fasting rats, in terms of stress response. A total of 20 male rats were randomly divided into a fasting group and a control group. Four weeks later, blood and urine samples were taken after decapitation. Analysis of CAs was done using high-performance liquid chromatography with florescence detection (HPLC-FLD). The dopamine (DA), adrenaline (ADR) and noradrenaline (NA) blood and urine concentrations were found to be higher in the fasting group compared to the control group, but the difference was statistically significant only for the blood DA levels (p < 0.05). In the fasting group, the blood values of ADR and NA correlated with each other but not with the DA levels, whereas there was correlation among the urine levels of DA, ADR and NA. In the control group, the blood and urine values of DA, ADR and NA correlated with each other. The differences observed in the blood and urine CAs indicate a specific regulation of CAs in Ramadan-type fasting, which needs to be investigated thoroughly in future studies.

Reward-based hypertension control by a synthetic brain–dopamine interface

Synthetic biology has significantly advanced the design of synthetic trigger-controlled devices that can reprogram mammalian cells to interface with complex metabolic activities. In the brain, the neurotransmitter dopamine coordinates communication with target neurons via a set of dopamine receptors that control behavior associated with reward-driven learning. This dopamine transmission has recently been suggested to increase central sympathetic outflow, resulting in plasma dopamine levels that correlate with corresponding brain activities. By functionally rewiring the human dopamine receptor D1 (DRD1) via the second messenger cyclic adenosine monophosphate (cAMP) to synthetic promoters containing cAMP response element-binding protein 1(CREB1)-specific cAMP-responsive operator modules, we have designed a synthetic dopamine-sensitive transcription controller that reversibly fine-tunes specific target gene expression at physiologically relevant brain-derived plasma dopamine levels. Following implantation of circuit-transgenic human cell lines insulated by semipermeable immunoprotective microcontainers into mice, the designer device interfaced with dopamine-specific brain activities and produced a systemic expression response when the animal's reward system was stimulated by food, sexual arousal, or addictive drugs. Reward-triggered brain activities were able to remotely program peripheral therapeutic implants to produce sufficient amounts of the atrial natriuretic peptide, which reduced the blood pressure of hypertensive mice to the normal physiologic range. Seamless control of therapeutic transgenes by subconscious behavior may provide opportunities for treatment strategies of the future.

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report

We report a case in which selegiline, an irreversible monoamine oxidase B (MAO-B) inhibitor, greatly improved depressive symptoms in an adult with stage 5 treatment-resistant major depressive disorder. Four antidepressants and four augmentation therapies had previously been ineffective or intolerable, and electroconvulsive therapy had only a temporary effect. After 20 weeks of treatment with selegiline (10 mg/day), the patient’s score on the 17-item Hamilton Depression Rating Scale (HDRS) had decreased from 19 to 4 points. [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET) showed increased glucose metabolism in the bilateral basal ganglia after initiating selegiline treatment; blood dopamine levels were also increased after selegiline treatment. These results raise the possibility that selegiline enhances dopamin-ergic neural transmission in treatment-resistant depression, thus leading to an improvement in depressive symptoms.

The brain is one of the most important sources of dopamine in the systemic circulation in the perinatal period of ontogenesis in rats

This study was designed to test the authors' hypothesis that dopamine passes from dopamine-synthesizing cells in the brain to the systemic circulation prior to the formation of the blood-brain barrier during ontogenesis. High-performance liquid chromatography studies demonstrated that peripheral blood dopamine levels before formation of the blood-brain barrier-in rat fetuses and neonates-are significantly higher than after formation of the barrier in adult rats, providing indirect evidence in support of the hypothesis. Furthermore, formation of the blood-brain barrier is accompanied by a significant increase in dopamine levels in the rat brain. Direct evidence for the hypothesis was obtained in the form of a sharp decrease in blood dopamine levels in fetuses after lesioning of dopamine-synthesizing neurons in the brain by encephalectomy.

In hamsters the D 1 receptor antagonist SCH23390 depresses ventilation during hypoxia

During exposure of animals to hypoxia, brain and blood dopamine levels increase stimulating dopaminergic receptors which influence the integrated ventilatory response to low oxygen. The purpose of the present study is to test the hypothesis that in conscious hamsters, systemic antagonism of D 1 receptors would depress their breathing in air and in response to hypoxic and hypercapnic challenges. Nine male hamsters were treated with saline or 0.25 mg/kg SCH-23390 (SCH), a D 1 receptor antagonist that crosses the blood–brain barrier. Ventilation was determined using the barometric method, and oxygen consumption and CO 2 production were evaluated utilizing the flow-through method. During exposure to air, SCH decreased frequency of breathing. During exposure to hypoxia (10% oxygen in nitrogen), relative to saline, SCH-treated hamsters decreased minute ventilation by decreasing tidal volume and oxygen consumption but not CO 2 production. During exposure to hypercapnia (5% CO 2 in 95% O 2), frequency of breathing was decreased with SCH, but there was no significant effect on minute ventilation. Relative to saline treatment body temperature was lower in SCH-treated hamsters by 0.6 °C. These results demonstrate that in hamsters D 1 receptors can modulate control of ventilation in air and during hypoxia and hypercapnic exposures. Whether D 1 receptors located centrally or on carotid bodies modulate these effects is not clear from this study.

Geriatric Men at Altitude: Hypoxic Ventilatory Sensitivity and Blood Dopamine Changes

Background: Short-term exposure to high-altitude hypoxia increases hypoxic ventilatory sensitivity (HVS) in healthy humans. Dopamine (DA) is the implicated neurotransmitter in carotid body (CB) chemoreceptor response, and the microenvironmental conditions in CB tissue are comparable to blood. Continuous DA infusion affected ventilation in animals and humans. Age-related oscillations in blood DA levels may influence peripheral chemoreflexes. Objective: Hypoxic ventilatory responses (HVR) relative to blood DA concentration and its precursor, dihydroxyphenylalanine (DOPA) was measured in young and elderly men during short-term altitude adaptation. Methods: Nine elderly climbers (group 1: 61 ± 1.4 years) and 7 young healthy subjects (group 2: 23 ± 2 years) were tested at sea level on day 0, on day 3 after passive transport to 2,200 m, and on day 14 after climbing to 4,200 and 5,642 m. Results: Sea level HVR in group 1 was 47% lower than in group 2, accompanied by higher blood DOPA (300%) and DA (37%) content. Initial DA and DOPA concentrations showed a negative correlation with initial HVR but a positive correlation with age. Passive transport to middle altitude (2,200 m) increased HVS, doubling HVR slopes in groups 1 and 2 and producing increased maximum expired minute ventilation during isocapnic rebreathing (29 and 28%, respectively). Day 3 2,200-meter blood DOPA content decreased by 22% in group 1 and increased by 300% in group 2. DA increased in both groups. Conclusion: The relationship between HVR and the reciprocal DA and DOPA values seen in both groups is associated with age, producing decreased DA receptor sensitivity and enhanced DA reuptake during adaptation to high altitude.

Spontaneous tumors in aging female mice are more prevalent in the lateral pituitary zones

The localization of gross and microscopic spontaneous pituitary tumors was examined in aging female C57BL/6J mice. These tumors were lactotroph adenomas, by morphological and immunocytochemical criteria. Each lobe of the pars distalis was divided into three zones of approximately equal size and the number of tumors in each zone was counted. Twelve out of 30 tumors were located entirely within the most lateral zone. An additional 14 tumors occurred in both the most lateral and the interjacent zones. Thus, almost 90% of the observed tumors were localized in more lateral zones of the pars distalis (Chi-squared test, p<0.01). These findings support a hypothesis [16] that lower portal blood dopamine levels reaching lateral portions of the pars distalis are a factor in the higher incidence of lactotroph adenomas in these zones.

Restoration of pituitary prolactin synthesis and release by the administration of morphine to rats bearing a transplanted prolactin-secreting tumor.

Rats bearing transplanted prolactin-secreting tumors are known to have very high prolactin levels in the serum, reduced hypothalamic opiate concentrations, increasing hypothalamic dopamine synthesis and increased hypophyseal portal blood dopamine levels. Further, it has been shown that incubation in 3H-leucine of anterior pituitary glands from these tumor-bearing rats demonstrates a marked inhibition of 3H-prolactin synthesis and release. Using rats with the prolactin-secreting tumor MtTW15, we have found that 4 days of continuous administration of either morphine sulfate 1.44 mg daily or haloperidol 0.11 mg daily using and osmotic infusion pump caused a significant increase in the synthesis and release of 3H-prolactin from incubated pituitary gland compared to untreated tumor-bearing animals. Morphine may reduce hypothalamic dopamine release, whereas haloperidol is a direct dopamine receptor antagonist in achieving these effects.